Alyeska Investment Group
ADMA icon

Alyeska Investment Group’s ADMA Biologics ADMA Stock Holding History

Alyeska Investment Group’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-265,820
Closed -$468K – 695
2021
Q1 		$468K Sell
265,820
-200,000
-43% -$458K 0.01% 679
2020
Q4 		$908K Sell
465,820
-503,727
-52% -$1.06M 0.01% 421
2020
Q3 		$2.32M Buy
969,547
+677,001
+231% +$1.86M 0.04% 335
2020
Q2 		$857K Buy
+292,546
New +$841K 0.01% 410
2019
Q3 		– Sell
-585,265
Closed -$2.27M – 398
2019
Q2 		$2.27M Buy
+585,265
New +$2.58M 0.03% 307
2016
Q1 		– Sell
-16,077
Closed -$130K – 379
2015
Q4 		$130K Sell
16,077
-39,866
-71% -$359K ﹤0.01% 365
2015
Q3 		$468K Buy
55,943
+5,120
+10% +$47.3K 0.01% 428
2015
Q2 		$471K Buy
50,823
+823
+2% +$7.12K 0.01% 454
2015
Q1 		$490K Buy
+50,000
New +$504K 0.01% 468

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Alyeska Investment Group's ADMA Position: Q2 2021 in Review

Alyeska Investment Group sold out of ADMA Biologics (ADMA) in Q2 2021, closing a stake of 265,820 shares — an estimated $468K sold.

Alyeska Investment Group first reported a position in ADMA in Q1 2015 and held it in 9 quarters. The position peaked at $2.32M in Q3 2020. 90 funds tracked by Wall St. Rank hold ADMA as of Q2 2021.

  • Alyeska Investment Group reported no remaining ADMA Biologics position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 265,820 ADMA Biologics shares in Q2 2021, an estimated $468K.
  • Alyeska Investment Group first reported a position in ADMA Biologics in Q1 2015 and held it in 9 quarters.
  • Alyeska Investment Group's ADMA Biologics position peaked at $2.32M in Q3 2020.
  • 90 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.